AdvisorShares Psychedelics ETF (NY:PSIL)

20.58 +0.49 (+2.44%)

Delayed Quote Updated: 1:29 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AdvisorShares Psychedelics ETF

< Previous 1 2 3 4 5 Next >

These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗

April 27, 2026

Via MarketBeat

Topics Government

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors ↗

March 09, 2026

Relmada stated that the therapy showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer.

Via Stocktwits

Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises ↗

February 25, 2026

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

Via Stocktwits

Topics Intellectual Property

HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’ ↗

February 17, 2026

The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said.

Via Stocktwits

NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition ↗

November 11, 2025

Via Stocktwits

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗

February 17, 2026

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗

February 17, 2026

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗

December 24, 2025

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Via Stocktwits

Topics ETFs

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗

December 19, 2025

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.

Via Stocktwits

Topics Cannabis ETFs Government

Why Did KTTA Stock Soar A Whopping 48% Today? ↗

November 28, 2025

The company announced the pricing of a public offering of 80 million shares of its common stock and said that the offering will extend its cash runway through at least the first half of 2028.

Via Stocktwits

Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug ↗

August 05, 2025

Quantum Biopharma's subsidiary, Huge Biopharma Australia, has cleared a regulatory milestone for its neuroprotective compound, Lucid-MS, in a Phase 1 trial.

Via Benzinga

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗

June 23, 2025

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Via Stocktwits

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors ↗

May 24, 2025

Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.

Via Benzinga

Topics Government

5 ETFs That Beat Market Turmoil With Gains Last Week ↗

February 10, 2025

Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs.

Via Benzinga

Topics ETFs Economy

High-Momentum ETFs Leading the Market This Year

February 07, 2025

Momentum investors looking to start 2025 off on good footing might look no further than these high-flying ETFs, each of which has returned 14% or more in 2025.

Via MarketBeat

Topics ETFs

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding ↗

January 29, 2025

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.

Via Stocktwits

Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗

January 28, 2025

The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.

Via Stocktwits

5 Best-Performing Sector ETFs Of Q4 ↗

January 02, 2025

In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders in the fourth quarter.

Via Talk Markets

Topics ETFs

Why Is Penny Stock Clearmind Gaining Today? ↗

December 24, 2024

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.

Via Benzinga

5 Best-Performing Sector ETFs Midway In Q4 ↗

November 16, 2024

In this article, we have highlighted five top-performing ETFs from different sectors that were the leaders over the past month.

Via Talk Markets

Topics ETFs

Top And Flop ETFs Of The First Half ↗

June 29, 2024

In this article, we have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.

Via Talk Markets

Topics ETFs

Best And Worst ETF Zones Of Q2 ↗

June 26, 2024

After the worst monthly decline in many months in April, global stock markets have staged a nice comeback on renewed Fed rate cut bets, ongoing artificial intelligence (AI) developments and strong...

Via Talk Markets

Topics Artificial Intelligence ETFs Economy

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment ↗

June 05, 2024

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.

Via Benzinga

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

Mental Health Mavericks: 3 Stocks Changing the Game ↗

February 21, 2024

Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.

Via InvestorPlace

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.